US45257L1089 - IMMP - A2H8YL (XNMS)
IMMUTEP LIMITED - AMERICAN DEPOSITARY SHARES Hinterlegungsschein
2,25 USD
Aktuelle Kurse von IMMUTEP LIMITED - AMERICAN DEPOSITARY SHARES
Börse | Ticker | Währung | Letzter Umsatz | Kurs | Tagesveränderung | Tagesveränderung % |
---|---|---|---|---|---|---|
NASDAQ |
IMMP
|
USD
|
19.09.2024 21:59
|
2,25 USD
| 2,23 USD | 0,90 % |
Performance
Tag | Woche | Monat | 3 Monate | 6 Monate | 1 Jahr | 5 Jahre |
---|---|---|---|---|---|---|
0,00 % | -12,79 % | -2,17 % | -12,79 % | -7,02 % | 14,21 % | 46,10 % |
Firmenprofil zu IMMUTEP LIMITED - AMERICAN DEPOSITARY SHARES Hinterlegungsschein
Immutep Limited, a biotechnology company, engages in the research and development of pharmaceutical product candidates. The company develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. Its lead product candidate is eftilagimod alpha (efti or IMP321), a recombinant protein that is in Phase IIb clinical trial as a chemoimmunotherapy combination for metastatic breast cancer. The company also develops TACTI-002, which is in a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer; TACTI-003 that is in Phase IIb clinical trial to treat HNSCC; and INSIGHT-004 and INSIGHT-003, which is in a Phase I clinical trial for the treatment of solid tumors, as well as INSIGHT-005 that is in Phase I/IIa clinical trial to treat solid tumors. Its other products include IMP761, an agonist of lymphocyte activation gene 3 for autoimmune disease; IMP701, an antagonist antibody that acts to stimulate T cell proliferation in cancer patients; and IMP731, a depleting antibody that removes T cells involved in autoimmunity. Immutep Limited has collaboration agreements with GlaxoSmithKline, Novartis, CYTLIMIC Inc., Merck & Co., Inc., Institute of Clinical Cancer Research, Merck KGaA, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. Immutep Limited was incorporated in 1987 and is based in Sydney, Australia.
Unternehmensdaten IMMUTEP LIMITED - AMERICAN DEPOSITARY SHARES Hinterlegungsschein
Name IMMUTEP LIMITED - AMERICAN DEPOSITARY SHARES
Firma Immutep Limited
Symbol IMMP
Website https://www.immutep.com
Heimatbörse
NASDAQ/NMS (GLOBAL MARKET)
WKN A2H8YL
ISIN US45257L1089
Wertpapierart Hinterlegungsschein
Sektor Healthcare
Branche Biotechnology
CEO Mr. Marc Voigt
Marktkapitalisierung 382 Mio
Land Australien
Währung USD
Mitarbeiter 0,0 T
Adresse Australia Square, 2000 Sydney
IPO Datum 2012-04-19
Aktien-Splits
Datum | Split |
---|---|
07.11.2019 | 1:10 |
28.12.2016 | 3:10 |
Aktien Kennungs-Wechsel
Datum | Von | Zu |
---|---|---|
01.12.2017 | PBMD | IMMP |
Ticker Symbole
Name | Symbol |
---|---|
Frankfurt | YP1A.F |
NASDAQ | IMMP |
Weitere Aktien
Investoren die IMMUTEP LIMITED - AMERICAN DEPOSITARY SHARES halten haben auch folgende Aktien im Depot:
Die Finanzplattform goSPATZ trackt und analysiert Investitionen und Portfolios.
Vom Wertpapier-Depot bis zum Crypto-Kauf.
Nützlich, simpel und kostenlos. Aktien, ETF, ETC, ETN, Indizes, Fonds, Anleihen, Zertifikate, Währungen, Optionen, Bezugsrechte.
Nützlich, simpel und kostenlos. Aktien, ETF, ETC, ETN, Indizes, Fonds, Anleihen, Zertifikate, Währungen, Optionen, Bezugsrechte.
All rights reserved © LCP GmbH 2024